Sight Sciences

Yahoo Finance • 28 days ago

Sight Sciences raises 2025 revenue guidance to $76M-$78M while accelerating TearCare commercialization

Earnings Call Insights: Sight Sciences (SGHT) Q3 2025 MANAGEMENT VIEW * Paul Badawi, Co-Founder, President, CEO & Director, reported, "Our strong third quarter results were driven by excellent performance by our Surgical Glaucoma team,... Full story

Yahoo Finance • 30 days ago

Sight Sciences to Present at Two Upcoming Investor Conferences

MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies in... Full story

Yahoo Finance • 2 months ago

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure

MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies in... Full story

Yahoo Finance • 3 months ago

Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies i... Full story

Yahoo Finance • 3 months ago

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments

MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies i... Full story

Yahoo Finance • 3 months ago

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

MENLO PARK, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies in... Full story

Yahoo Finance • 3 months ago

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

MENLO PARK, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies int... Full story

Yahoo Finance • 4 months ago

Sight Sciences stock rating upgraded by Lake Street on stabilizing business

Investing.com - Lake Street Capital Markets upgraded Sight Sciences Inc. (NASDAQ:SGHT) from Hold to Buy with a price target of $5.00 on Friday. The stock has shown strong momentum, gaining over 8.5% in the past week and trading at $4.13,... Full story

Yahoo Finance • 4 months ago

Sight Sciences raises 2025 revenue guidance to $72M–$76M amid strong OMNI growth and strategic focus on MIGS leadership

Earnings Call Insights: Sight Sciences (SGHT) Q2 2025 MANAGEMENT VIEW * Paul Badawi, CEO, highlighted "our strong second quarter performance underscores the value of our proven interventional technologies for treating glaucoma and dry... Full story

Yahoo Finance • 4 months ago

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

MENLO PARK, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative technology intended to transfor... Full story

Yahoo Finance • 4 months ago

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

MENLO PARK, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative technology intended to transform... Full story

Yahoo Finance • 4 months ago

Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to tran... Full story

Yahoo Finance • 7 months ago

Sight Sciences Appoints Gary Burbach to its Board of Directors

MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies... Full story

Yahoo Finance • 7 months ago

Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio

MENLO PARK, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) , an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eye care a... Full story

Yahoo Finance • 8 months ago

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologi... Full story

Yahoo Finance • 9 months ago

Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologi... Full story

Yahoo Finance • 9 months ago

Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

A Meta-Analysis of 22 Studies, and Data from the IRIS® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant, Long-Term IOP Reduction and Medication Reduction with the OMNI® Surgical System MENL... Full story

Yahoo Finance • 10 months ago

Sight Sciences to Present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day

MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologie... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sight Sciences, Inc. (NASDAQ: SGHT) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Sight Sciences, Inc. (NASDAQ: SGHT) (“Sight Sciences”) on behalf of the company’s investors. Since January 2023, shares of Sight Sciences... Full story

Yahoo Finance • 2 years ago

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to tran... Full story